Susan B. Trujillo quoted in article "3 Takeaways From FDA's Drug Compounding Guidances"

Below is an excerpt:

Quarles & Brady LLP partner Susan B. Trujillo predicted that the FDA's position will draw fire from 503B outsourcing facilities that invested heavily in manufacturing upgrades but expected to maintain the capacity to operate more flexibly in certain areas as 503A pharmacies.

"I think this is going to have a big impact, especially in places that have already put an outsourcing facility at a location," Trujillo said.

Resources